Gwendolen Y Chang, MD
Nephrology · San Leandro
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 5 carriers
- Office
- 1
- Since medical school
- 19 years
- Stanford University School of Medicine, 2007
Offices
1 location · West Coast Kidney · 56 clinicians in this group
Hospitals listed: 052675 · 052742 · 552749 · Eden Medical Center · Highland Hospital. That is not proof they admit you there this week.
Plans that list them
21 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chang’s office at (510) 351-9373 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A106132 · Current
Licensed to practise in California · since 2008 · expires 2028-08-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hospice and Palliative Medicine
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Nephrology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$295,114
Medicare paid this office $295,114 for 488 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 40 | $80,895 | $314 |
| Return visit (30+ min) | 176 | $37,887 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 140 | $37,496 | $105 |
| Critical care, first 30-74 minutes | 38 | $18,899 | $183 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $13,587 | $149 |
See all 16 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 40 | $80,895 | $314 |
| Return visit (30+ min) | 176 | $37,887 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 140 | $37,496 | $105 |
| Critical care, first 30-74 minutes | 38 | $18,899 | $183 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $13,587 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 93 | $12,302 | $70 |
| Long return visit (40+ min) | 57 | $12,170 | $162 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 45 | $12,017 | $59 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $11,512 | $262 |
| Hemodialysis procedure with physician evaluation | 52 | $6,128 | $63 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 45 | $5,841 | $46 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 187 | $5,442 | $14 |
| Transitional care management services for problem of high complexity | 17 | $5,150 | $271 |
| New patient visit (60+ min) | 28 | $4,929 | $176 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,912 | $115 |
| New patient visit (45+ min) | 11 | $903 | $82 |
Who their Medicare patients are
488 Original Medicare patients in 2024. Average age 74 · Under 65 14% · 85 and older 18% · Women 49% · Also on Medicaid 73% · Health risk score 4.52. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 67% · Heart failure 49% · Coronary heart disease 38% · COPD 31% · Atrial fibrillation 30% · Depression 26% · Stroke 23% · Dementia 17% · Cancer 14%.
The office billed $805,591, Medicare allowed $386,803 and paid $295,114; for 2,601 services of 35 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 488 | 2,601 | 74 | 4.52 | $805,591 | $295,114 |
| 2023 | 465 | 2,104 | 73 | 4.76 | $725,590 | $274,574 |
| 2022 | 483 | 2,102 | 72 | 4.46 | $700,077 | $259,747 |
| 2021 | 311 | 1,280 | 72 | 4.71 | $477,903 | $187,637 |
| 2020 | 373 | 1,620 | 70 | 5.38 | $521,880 | $201,799 |
| 2019 | 397 | 1,461 | 71 | 5.24 | $453,313 | $173,102 |
| 2018 | 393 | 1,556 | 71 | 5.04 | $480,502 | $181,867 |
| 2017 | 431 | 2,012 | 71 | 5.24 | $562,028 | $208,343 |
| 2016 | 418 | 1,875 | 71 | 5.11 | $464,996 | $181,203 |
| 2015 | 435 | 2,472 | 69 | 5.44 | $588,349 | $235,827 |
| 2014 | 407 | 2,292 | 70 | 5.12 | $505,998 | $213,381 |
| 2013 | 196 | 805 | 71 | 4.77 | $137,098 | $63,082 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 38 | $96,295 | $320 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 130 | $44,788 | $103 |
| Return visit (30+ min) | 168 | $32,626 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 99 | $16,883 | $70 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 20 | $13,967 | $269 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $11,427 | $154 |
| Hemodialysis procedure with physician evaluation | 71 | $7,426 | $63 |
| New patient visit (45+ min) | 46 | $6,244 | $136 |
| Long return visit (40+ min) | 28 | $5,877 | $143 |
| Critical care, first 30-74 minutes | 17 | $5,495 | $183 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 42 | $5,413 | $118 |
| New patient visit (60+ min) | 12 | $2,438 | $203 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,226 | $102 |
2022: 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 42 | $90,926 | $315 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 156 | $36,761 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 137 | $26,532 | $63 |
| Return visit (30+ min) | 129 | $24,353 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $16,909 | $174 |
| Hemodialysis procedure with physician evaluation | 68 | $11,543 | $63 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 21 | $10,326 | $252 |
| Long return visit (40+ min) | 33 | $6,810 | $142 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $6,136 | $116 |
| Telephone medical discussion with physician, 21-30 minutes | 47 | $5,137 | $74 |
| New patient visit (45+ min) | 37 | $3,955 | $107 |
| New patient visit (60+ min) | 17 | $3,317 | $195 |
| Dialysis procedure including 1 evaluation | 11 | $1,420 | $79 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $1,326 | $63 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 26 | $1,169 | $34 |
2021: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 44 | $85,279 | $324 |
| Return visit (30+ min) | 109 | $23,243 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 69 | $14,836 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $12,313 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,929 | $178 |
| Hemodialysis procedure with physician evaluation | 41 | $6,477 | $64 |
| Telephone medical discussion with physician, 21-30 minutes | 43 | $6,050 | $121 |
| Long return visit (40+ min) | 25 | $5,864 | $163 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $5,061 | $123 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $4,959 | $261 |
| New patient visit (45+ min) | 29 | $4,001 | $138 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,582 | $88 |
2020: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 46 | $87,794 | $261 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 111 | $22,477 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 116 | $16,710 | $65 |
| Hemodialysis procedure with physician evaluation | 77 | $16,348 | $67 |
| Return visit (30+ min) | 87 | $14,538 | $83 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $8,989 | $225 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,871 | $186 |
| Long return visit (40+ min) | 25 | $4,766 | $132 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $4,018 | $122 |
| New patient visit (45+ min) | 23 | $2,989 | $130 |
| Hemodialysis procedure requiring repeated evaluation | 11 | $1,155 | $96 |
2019: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 51 | $71,967 | $257 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 116 | $25,307 | $91 |
| Return visit (30+ min) | 97 | $18,227 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 102 | $11,454 | $63 |
| Hemodialysis procedure with physician evaluation | 74 | $11,247 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $8,044 | $179 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $5,853 | $217 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,121 | $118 |
| Long return visit (40+ min) | 22 | $3,789 | $131 |
| New patient visit (45+ min) | 25 | $3,220 | $129 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $383 | $32 |
2018: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 38 | $74,951 | $255 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $29,882 | $92 |
| Return visit (30+ min) | 89 | $16,889 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 109 | $14,618 | $64 |
| Hemodialysis procedure with physician evaluation | 67 | $10,725 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $10,492 | $172 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $5,080 | $118 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $4,744 | $216 |
| Critical care, first 30-74 minutes | 12 | $4,077 | $194 |
| New patient visit (45+ min) | 12 | $1,687 | $141 |
| Short return visit (20+ min) | 31 | $1,337 | $39 |
2017: 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 45 | $80,819 | $243 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 140 | $31,102 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 132 | $16,281 | $62 |
| Critical care, first 30-74 minutes | 41 | $13,444 | $192 |
| Hemodialysis procedure with physician evaluation | 83 | $10,950 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $9,116 | $166 |
| Short return visit (20+ min) | 69 | $7,333 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $6,915 | $115 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 22 | $6,655 | $208 |
| Return visit (30+ min) | 36 | $6,234 | $92 |
| New patient visit (45+ min) | 13 | $1,634 | $126 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,315 | $88 |
| Hemodialysis procedure requiring repeated evaluation | 12 | $1,270 | $91 |
| New patient visit (30+ min) | 14 | $1,231 | $88 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $512 | $34 |
2016: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 47 | $59,572 | $243 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 125 | $26,877 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 148 | $18,414 | $62 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 38 | $11,402 | $200 |
| Hemodialysis procedure with physician evaluation | 77 | $9,491 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $9,388 | $174 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 72 | $9,377 | $114 |
| Critical care, first 30-74 minutes | 18 | $7,949 | $189 |
| Short return visit (20+ min) | 72 | $6,717 | $54 |
| Return visit (30+ min) | 31 | $4,735 | $88 |
| New patient visit (30+ min) | 22 | $1,727 | $79 |
2015: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 56 | $64,779 | $246 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 127 | $35,987 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 190 | $33,906 | $62 |
| Hemodialysis procedure with physician evaluation | 87 | $20,165 | $61 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 37 | $15,993 | $202 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 99 | $13,877 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,901 | $171 |
| Critical care, first 30-74 minutes | 18 | $6,845 | $190 |
| Return visit (30+ min) | 35 | $5,652 | $83 |
| Short return visit (20+ min) | 58 | $5,265 | $57 |
| New patient visit (30+ min) | 21 | $1,740 | $83 |
| New patient visit (45+ min) | 13 | $1,613 | $124 |
| Hemodialysis procedure requiring repeated evaluation | 14 | $1,612 | $81 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 32 | $1,209 | $34 |
2014: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 38 | $60,584 | $246 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 204 | $43,756 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 146 | $38,127 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 91 | $16,512 | $174 |
| Hemodialysis procedure with physician evaluation | 85 | $14,241 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 90 | $11,646 | $116 |
| Return visit (30+ min) | 35 | $5,583 | $90 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 11 | $3,761 | $209 |
| Short return visit (20+ min) | 31 | $2,745 | $56 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 58 | $2,684 | $34 |
| New patient visit (45+ min) | 17 | $2,456 | $144 |
| Hemodialysis procedure requiring repeated evaluation | 13 | $1,615 | $90 |
2013: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $19,467 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 82 | $10,871 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,590 | $169 |
| Hemodialysis procedure with physician evaluation | 36 | $5,090 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,923 | $114 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 37 | $1,788 | $33 |
| Return visit (30+ min) | 13 | $1,714 | $95 |
| Short return visit (20+ min) | 14 | $1,172 | $65 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,093 | $84 |
Medicaid work
$99,269 in 2024
Medicaid paid $99,269 for 1,508 billed services this clinician did in 2024, up to 40 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 303 | $44,039 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 471 | $24,512 |
| Return visit (30+ min) | 273 | $10,217 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 194 | $6,410 |
| 1ST HOSP IP/OBS HIGH 75 | 74 | $6,031 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 142 | $5,885 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 26 | $1,717 |
| Long return visit (40+ min) | 12 | $305 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (List separately in addition to code for primary procedure) | 13 | $153 |
| 2024 | 1,508 | 9 | 40 | $99,269 |
| 2023 | 1,607 | 7 | 35 | $113,888 |
| 2022 | 1,518 | 7 | 33 | $85,167 |
| 2021 | 1,223 | 8 | 38 | $55,294 |
| 2020 | 1,256 | 6 | 39 | $71,747 |
| 2019 | 1,200 | 5 | 46 | $60,505 |
| 2018 | 1,365 | 5 | 47 | $59,404 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 323 | $60,129 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 493 | $25,599 |
| Return visit (30+ min) | 322 | $9,235 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 276 | $8,023 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 143 | $5,725 |
| 1ST HOSP IP/OBS HIGH 75 | 38 | $3,112 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 12 | $2,066 |
2022
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 329 | $48,703 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 379 | $16,390 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 453 | $11,070 |
| Return visit (30+ min) | 192 | $3,797 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 121 | $2,903 |
| 1ST HOSP IP/OBS HIGH 75 | 30 | $1,326 |
| Long return visit (40+ min) | 14 | $977 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 322 | $41,431 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 258 | $6,565 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 95 | $2,851 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 90 | $2,330 |
| Return visit (30+ min) | 128 | $1,521 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose | 12 | $320 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose | 12 | $274 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 306 | $0 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 426 | $51,399 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 209 | $7,443 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 237 | $6,640 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 123 | $3,444 |
| Return visit (30+ min) | 121 | $2,821 |
| UNLISTED DIALYSIS PROCEDURE INPATIENT/OUTPATIENT | 140 | $0 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 352 | $37,483 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 294 | $9,174 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 204 | $6,945 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 193 | $4,126 |
| Return visit (30+ min) | 157 | $2,778 |
2018
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 397 | $34,697 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 334 | $9,398 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 271 | $8,590 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 207 | $3,563 |
| Return visit (30+ min) | 156 | $3,157 |
Drugs they prescribed that Part D paid
$942,374
Pharmacies billed $942,374 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,140) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,581 generic and fewer than 11 brand-name prescriptions · $942,374 in drug cost · 40 antibiotic prescriptions to 24 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jynarque | 11 | $186,839 | $16,985 |
| Farxiga | 176 | $142,152 | $808 |
| Rayaldee | 57 | $68,619 | $1,204 |
| Veltassa | 52 | $60,625 | $1,166 |
| Xphozah | 17 | $53,703 | $3,159 |
See all 45 drugs
| Jynarque | 11 | $186,839 | $16,985 |
| Farxiga | 176 | $142,152 | $808 |
| Rayaldee | 57 | $68,619 | $1,204 |
| Veltassa | 52 | $60,625 | $1,166 |
| Xphozah | 17 | $53,703 | $3,159 |
| Lokelma | 55 | $45,895 | $834 |
| Jardiance | 43 | $45,564 | $1,060 |
| Sevelamer Carbonate | 57 | $22,834 | $401 |
| Aranesp | 19 | $14,103 | $742 |
| Lanthanum Carbonate | 18 | $14,021 | $779 |
| Dapagliflozin | 14 | $9,995 | $714 |
| Januvia | 13 | $7,146 | $550 |
| Clinolipid | 14 | $3,645 | $260 |
| Febuxostat | 46 | $3,615 | $79 |
| Procrit | 14 | $3,199 | $228 |
| Bumetanide | 110 | $3,060 | $28 |
| Calcium Acetate | 17 | $1,457 | $86 |
| Amlodipine Besylate | 260 | $1,104 | $4 |
| Potassium Citrate Er | 11 | $937 | $85 |
| Allopurinol | 105 | $900 | $9 |
| Potassium Chloride | 33 | $708 | $21 |
| Losartan | 101 | $679 | $7 |
| Hydralazine | 49 | $602 | $12 |
| Chlorthalidone | 21 | $516 | $25 |
| Pantoprazole | 38 | $433 | $11 |
| Lisinopril | 82 | $392 | $5 |
| Calcitriol | 29 | $387 | $13 |
| Atorvastatin | 39 | $358 | $9 |
| Metoprolol | 21 | $320 | $15 |
| Furosemide | 118 | $319 | $3 |
| Olmesartan Medoxomil | 21 | $304 | $14 |
| Carvedilol | 31 | $241 | $8 |
| Tamsulosin | 26 | $225 | $9 |
| Cephalexin | 27 | $143 | $5 |
| Clonidine | 22 | $132 | $6 |
| Metoprolol | 11 | $125 | $11 |
| Glipizide | 21 | $122 | $6 |
| Atenolol | 19 | $101 | $5 |
| Gabapentin | 16 | $93 | $6 |
| Levothyroxine | 14 | $92 | $7 |
| Ciprofloxacin | 12 | $61 | $5 |
| Metformin | 14 | $57 | $4 |
| Metformin Hcl Er | 16 | $54 | $3 |
| Prednisone | 15 | $47 | $3 |
| Hydrochlorothiazide | 12 | $19 | $2 |
Year by year
| 2024 | 2,140 | 243 | 0% (0) | None | $942,374 |
| 2023 | 1,647 | 204 | 0% (0) | None | $1,564,859 |
| 2022 | 1,408 | 186 | 0% (0) | None | $874,596 |
| 2021 | 1,075 | 144 | 0% (0) | None | $304,164 |
| 2020 | 1,118 | 134 | 0% (0) | None | $512,054 |
| 2019 | 1,068 | 135 | 0% (0) | 22% | $233,288 |
| 2018 | 1,244 | 127 | 0% (0) | 23% | $993,044 |
| 2017 | 1,346 | 129 | None | 28% | $310,785 |
| 2016 | 1,193 | 124 | 0% (0) | 22% | $264,451 |
| 2015 | 724 | 103 | None | 35% | $214,498 |
| 2014 | 402 | 63 | None | None | $109,613 |
| 2013 | 23 | None | None | None | $2,082 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 38 drugs
| Cortrophin | 12 | $843,518 | $70,293 |
| Jynarque | 18 | $333,926 | $18,551 |
| Veltassa | 54 | $66,545 | $1,232 |
| Rayaldee | 42 | $58,118 | $1,384 |
| Lokelma | 50 | $49,726 | $995 |
| Farxiga | 45 | $37,455 | $832 |
| Jardiance | 15 | $19,827 | $1,322 |
| Sevelamer Carbonate | 29 | $15,042 | $519 |
| Renvela | 16 | $10,490 | $656 |
| Febuxostat | 18 | $9,581 | $532 |
| Aranesp | 11 | $8,413 | $765 |
| Bumetanide | 99 | $4,845 | $49 |
| Clinolipid | 19 | $4,800 | $253 |
| Amlodipine Besylate | 172 | $3,091 | $18 |
| Calcium Acetate | 24 | $2,642 | $110 |
| Allopurinol | 128 | $2,291 | $18 |
| Losartan | 83 | $1,500 | $18 |
| Hydralazine | 37 | $1,411 | $38 |
| Lisinopril | 78 | $1,310 | $17 |
| Furosemide | 125 | $1,160 | $9 |
| Potassium Chloride | 31 | $865 | $28 |
| Calcitriol | 31 | $775 | $25 |
| Metoprolol | 19 | $607 | $32 |
| Clonidine | 31 | $502 | $16 |
| Hydroxyzine | 22 | $498 | $23 |
| Olmesartan Medoxomil | 19 | $486 | $26 |
| Pantoprazole | 26 | $461 | $18 |
| Carvedilol | 30 | $456 | $15 |
| Atorvastatin | 27 | $438 | $16 |
| Glipizide | 27 | $412 | $15 |
| Metoprolol | 12 | $225 | $19 |
| Spironolactone | 14 | $134 | $10 |
| Colchicine | 13 | $127 | $10 |
| Ciprofloxacin | 14 | $118 | $8 |
| Cephalexin | 14 | $87 | $6 |
| Atenolol | 11 | $74 | $7 |
| Clopidogrel | 12 | $59 | $5 |
| Gabapentin | 11 | $43 | $4 |
2022: 32 drugs
| Velphoro | 19 | $95,276 | $5,015 |
| Lokelma | 52 | $59,948 | $1,153 |
| Rayaldee | 42 | $51,830 | $1,234 |
| Veltassa | 29 | $30,013 | $1,035 |
| Sevelamer Carbonate | 36 | $23,020 | $639 |
| Renvela | 16 | $16,276 | $1,017 |
| Jardiance | 16 | $15,991 | $999 |
| Aranesp | 11 | $9,760 | $887 |
| Febuxostat | 27 | $7,862 | $291 |
| Retacrit | 19 | $5,586 | $294 |
| Bumetanide | 59 | $3,720 | $63 |
| Calcium Acetate | 21 | $3,236 | $154 |
| Potassium Citrate Er | 12 | $2,316 | $193 |
| Allopurinol | 99 | $1,481 | $15 |
| Hydralazine | 51 | $1,357 | $27 |
| Losartan | 63 | $902 | $14 |
| Calcitriol | 33 | $835 | $25 |
| Amlodipine Besylate | 115 | $751 | $7 |
| Lisinopril | 88 | $718 | $8 |
| Furosemide | 102 | $664 | $7 |
| Potassium Chloride | 25 | $609 | $24 |
| Hydroxyzine | 32 | $450 | $14 |
| Olmesartan Medoxomil | 14 | $415 | $30 |
| Carvedilol | 33 | $303 | $9 |
| Metoprolol | 18 | $271 | $15 |
| Atorvastatin | 24 | $264 | $11 |
| Clonidine | 31 | $251 | $8 |
| Spironolactone | 11 | $141 | $13 |
| Tamsulosin | 11 | $99 | $9 |
| Cephalexin | 23 | $81 | $4 |
| Ciprofloxacin | 11 | $61 | $6 |
| Clopidogrel | 13 | $24 | $2 |
2021: 30 drugs
| Velphoro | 21 | $90,009 | $4,286 |
| Lokelma | 39 | $40,284 | $1,033 |
| Renvela | 20 | $27,526 | $1,376 |
| Veltassa | 19 | $18,044 | $950 |
| Rayaldee | 13 | $15,780 | $1,214 |
| Sevelamer Carbonate | 26 | $14,604 | $562 |
| Jardiance | 21 | $12,980 | $618 |
| Retacrit | 25 | $8,330 | $333 |
| Bumetanide | 42 | $3,164 | $75 |
| Febuxostat | 21 | $2,863 | $136 |
| Calcitriol | 45 | $1,491 | $33 |
| Hydralazine | 54 | $1,235 | $23 |
| Potassium Citrate Er | 11 | $1,195 | $109 |
| Allopurinol | 73 | $949 | $13 |
| Olmesartan Medoxomil | 11 | $801 | $73 |
| Amlodipine Besylate | 99 | $708 | $7 |
| Labetalol | 11 | $621 | $56 |
| Furosemide | 68 | $520 | $8 |
| Metoprolol | 14 | $340 | $24 |
| Losartan | 31 | $336 | $11 |
| Levothyroxine | 13 | $301 | $23 |
| Potassium Chloride | 14 | $285 | $20 |
| Tamsulosin | 12 | $238 | $20 |
| Atorvastatin | 17 | $232 | $14 |
| Carvedilol | 26 | $229 | $9 |
| Lisinopril | 58 | $218 | $4 |
| Clonidine | 37 | $205 | $6 |
| Atenolol | 11 | $173 | $16 |
| Cephalexin | 12 | $72 | $6 |
| Hydrochlorothiazide | 15 | $41 | $3 |
2020: 32 drugs
| Velphoro | 22 | $89,587 | $4,072 |
| Lokelma | 40 | $32,180 | $805 |
| Renvela | 20 | $30,006 | $1,500 |
| Rayaldee | 23 | $25,970 | $1,129 |
| Procrit | 18 | $17,002 | $945 |
| Veltassa | 20 | $16,739 | $837 |
| Sevelamer Carbonate | 30 | $16,627 | $554 |
| Retacrit | 29 | $5,728 | $198 |
| Febuxostat | 22 | $4,603 | $209 |
| Cinacalcet | 12 | $3,598 | $300 |
| Calcium Acetate | 14 | $1,932 | $138 |
| Potassium Citrate Er | 12 | $1,473 | $123 |
| Hydralazine | 38 | $1,432 | $38 |
| Bumetanide | 27 | $1,428 | $53 |
| Calcitriol | 38 | $1,419 | $37 |
| Olmesartan Medoxomil | 13 | $1,131 | $87 |
| Furosemide | 113 | $846 | $7 |
| Clonidine | 43 | $681 | $16 |
| Allopurinol | 61 | $583 | $10 |
| Labetalol | 13 | $527 | $41 |
| Amlodipine Besylate | 86 | $447 | $5 |
| Losartan | 37 | $382 | $10 |
| Metoprolol | 11 | $336 | $31 |
| Atorvastatin | 25 | $309 | $12 |
| Lisinopril | 64 | $295 | $5 |
| Potassium Chloride | 13 | $292 | $22 |
| Levothyroxine | 12 | $270 | $23 |
| Midodrine | 16 | $233 | $15 |
| Tamsulosin | 14 | $217 | $15 |
| Carvedilol | 35 | $186 | $5 |
| Cephalexin | 13 | $53 | $4 |
| Hydrochlorothiazide | 12 | $17 | $1 |
2019: 24 drugs
| Velphoro | 17 | $47,636 | $2,802 |
| Sevelamer Carbonate | 37 | $40,009 | $1,081 |
| Veltassa | 31 | $28,531 | $920 |
| Renvela | 18 | $21,435 | $1,191 |
| Sensipar | 15 | $20,385 | $1,359 |
| Procrit | 18 | $17,399 | $967 |
| Prosol | 22 | $2,768 | $126 |
| Calcium Acetate | 19 | $1,613 | $85 |
| Furosemide | 100 | $1,280 | $13 |
| Hydralazine | 54 | $1,254 | $23 |
| Allopurinol | 87 | $1,174 | $13 |
| Nifedipine Er | 12 | $1,000 | $83 |
| Calcitriol | 29 | $916 | $32 |
| Clonidine | 49 | $722 | $15 |
| Amlodipine Besylate | 91 | $542 | $6 |
| Carvedilol | 32 | $420 | $13 |
| Lisinopril | 47 | $416 | $9 |
| Tamsulosin | 20 | $406 | $20 |
| Losartan | 32 | $343 | $11 |
| Finasteride | 15 | $342 | $23 |
| Potassium Chloride | 21 | $315 | $15 |
| Atorvastatin | 16 | $194 | $12 |
| Hydrochlorothiazide | 26 | $133 | $5 |
| Cephalexin | 11 | $65 | $6 |
2018: 29 drugs
| Renvela | 35 | $71,904 | $2,054 |
| Sevelamer Carbonate | 42 | $60,113 | $1,431 |
| Velphoro | 13 | $26,164 | $2,013 |
| Veltassa | 21 | $22,021 | $1,049 |
| Procrit | 12 | $14,195 | $1,183 |
| Januvia | 13 | $9,926 | $764 |
| Prosol | 51 | $6,490 | $127 |
| Uloric | 13 | $6,320 | $486 |
| Calcium Acetate | 31 | $3,153 | $102 |
| Allopurinol | 96 | $1,140 | $12 |
| Hydralazine | 49 | $1,139 | $23 |
| Calcitriol | 39 | $949 | $24 |
| Furosemide | 100 | $891 | $9 |
| Nifedipine Er | 17 | $827 | $49 |
| Clonidine | 66 | $812 | $12 |
| Amlodipine Besylate | 127 | $768 | $6 |
| Labetalol | 14 | $672 | $48 |
| Midodrine | 21 | $568 | $27 |
| Losartan | 51 | $399 | $8 |
| Lisinopril | 55 | $335 | $6 |
| Atorvastatin | 21 | $321 | $15 |
| Tamsulosin | 22 | $318 | $14 |
| Levothyroxine | 11 | $308 | $28 |
| Enalapril Maleate | 16 | $305 | $19 |
| Insulin | 11 | $274 | $25 |
| Carvedilol | 27 | $220 | $8 |
| Spironolactone | 15 | $206 | $14 |
| Hydrochlorothiazide | 15 | $144 | $10 |
| Ciprofloxacin | 12 | $48 | $4 |
2017: 35 drugs
| Renvela | 84 | $141,287 | $1,682 |
| Sensipar | 47 | $57,363 | $1,220 |
| Procrit | 19 | $14,354 | $755 |
| Velphoro | 12 | $12,764 | $1,064 |
| Prosol | 43 | $7,445 | $173 |
| Calcium Acetate | 36 | $4,329 | $120 |
| Lantus | 17 | $4,321 | $254 |
| Colchicine | 12 | $2,135 | $178 |
| Isosorbide Dinitrate | 20 | $2,022 | $101 |
| Bumetanide | 15 | $1,114 | $74 |
| Hydralazine | 57 | $1,000 | $18 |
| Calcitriol | 36 | $956 | $27 |
| Labetalol | 24 | $734 | $31 |
| Clonidine | 84 | $722 | $9 |
| Allopurinol | 42 | $678 | $16 |
| Nifedipine Er | 22 | $651 | $30 |
| Amlodipine Besylate | 142 | $586 | $4 |
| Enalapril Maleate | 25 | $507 | $20 |
| Furosemide | 86 | $474 | $6 |
| Spironolactone | 29 | $377 | $13 |
| Insulin | 20 | $329 | $16 |
| Midodrine | 18 | $205 | $11 |
| Lisinopril | 35 | $196 | $6 |
| Prednisone | 16 | $182 | $11 |
| Metoprolol | 18 | $179 | $10 |
| Atenolol | 30 | $169 | $6 |
| Hydrochlorothiazide | 22 | $166 | $8 |
| Losartan | 19 | $124 | $7 |
| Atorvastatin | 22 | $123 | $6 |
| Glipizide | 16 | $96 | $6 |
| Carvedilol | 11 | $90 | $8 |
| Ciprofloxacin | 11 | $67 | $6 |
| Simvastatin | 15 | $50 | $3 |
| Warfarin | 18 | $27 | $2 |
| Lactulose | 13 | $26 | $2 |
2016: 31 drugs
| Renvela | 78 | $151,296 | $1,940 |
| Sensipar | 37 | $37,181 | $1,005 |
| Procrit | 12 | $6,179 | $515 |
| Lantus | 18 | $4,555 | $253 |
| Novolog | 12 | $4,133 | $344 |
| Lantus Solostar | 11 | $4,109 | $374 |
| Calcium Acetate | 26 | $3,513 | $135 |
| Hydralazine | 81 | $1,285 | $16 |
| Bumetanide | 17 | $839 | $49 |
| Labetalol | 16 | $802 | $50 |
| Amlodipine Besylate | 150 | $696 | $5 |
| Calcitriol | 24 | $571 | $24 |
| Allopurinol | 45 | $445 | $10 |
| Mercaptopurine | 11 | $443 | $40 |
| Clonidine | 70 | $422 | $6 |
| Atenolol | 30 | $355 | $12 |
| Lidocaine-Prilocaine | 12 | $330 | $28 |
| Enalapril Maleate | 16 | $303 | $19 |
| Lisinopril | 55 | $271 | $5 |
| Furosemide | 46 | $262 | $6 |
| Midodrine | 17 | $250 | $15 |
| Insulin | 16 | $233 | $15 |
| Metoprolol | 11 | $207 | $19 |
| Hydrochlorothiazide | 36 | $192 | $5 |
| Losartan | 35 | $187 | $5 |
| Carvedilol | 19 | $142 | $7 |
| Omeprazole | 17 | $122 | $7 |
| Atorvastatin | 15 | $113 | $8 |
| Glipizide | 28 | $91 | $3 |
| Metoprolol | 22 | $89 | $4 |
| Simvastatin | 12 | $39 | $3 |
2015: 19 drugs
| Renvela | 75 | $135,847 | $1,811 |
| Sensipar | 29 | $36,740 | $1,267 |
| Procrit | 13 | $11,573 | $890 |
| Lantus | 21 | $5,509 | $262 |
| Calcium Acetate | 27 | $3,471 | $129 |
| Eplerenone | 12 | $1,332 | $111 |
| Hydralazine | 40 | $652 | $16 |
| Lidocaine-Prilocaine | 17 | $527 | $31 |
| Amlodipine Besylate | 72 | $502 | $7 |
| Clonidine | 34 | $223 | $7 |
| Lisinopril | 36 | $221 | $6 |
| Losartan | 25 | $216 | $9 |
| Allopurinol | 17 | $197 | $12 |
| Furosemide | 28 | $183 | $7 |
| Atenolol | 17 | $165 | $10 |
| Nortriptyline | 12 | $142 | $12 |
| Omeprazole | 24 | $140 | $6 |
| Metoprolol | 13 | $75 | $6 |
| Glipizide | 13 | $62 | $5 |
2014: 9 drugs
| Renvela | 38 | $63,891 | $1,681 |
| Sensipar | 20 | $19,457 | $973 |
| Procrit | 11 | $9,571 | $870 |
| Calcium Acetate | 30 | $5,078 | $169 |
| Furosemide | 41 | $308 | $8 |
| Losartan | 23 | $224 | $10 |
| Amlodipine Besylate | 30 | $223 | $7 |
| Clonidine | 20 | $198 | $10 |
| Allopurinol | 15 | $146 | $10 |
Money from drug and device companies
$1,616 in 2025
| 2025 | 15 | 68 | None | $1,616 |
| 2024 | 16 | 53 | None | $1,284 |
| 2023 | 13 | 51 | None | $1,024 |
| 2022 | 8 | 21 | None | $519 |
| 2021 | 4 | 5 | None | $80 |
| 2020 | 5 | 29 | None | $526 |
| 2019 | 4 | 4 | None | $101 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Fresenius USA Marketing | Velphoro | $466 | 22 payments
|
| Novartis Pharmaceuticals | Fabhalta | $226 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $207 | 9 payments
|
| Otsuka America Pharmaceutical | Jynarque | $186 | 8 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $89 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $72 | 3 payments
|
See all 68 published payments
| Calliditas Therapeutics US | Meals · 2025-12-16 | Tarpeyo | $27 |
| Fresenius USA Marketing | Meals · 2025-12-16 | Velphoro | $24 |
| Fresenius USA Marketing | Meals · 2025-12-11 | Velphoro | $7 |
| Fresenius USA Marketing | Meals · 2025-12-11 | Velphoro | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-10 | Farxiga | $28 |
| Otsuka America Pharmaceutical | Meals · 2025-12-04 | Jynarque | $30 |
| Fresenius USA Marketing | Meals · 2025-12-02 | Velphoro | $22 |
| Ardelyx | Meals · 2025-11-26 | Ibsrela | $28 |
| Calliditas Therapeutics US | Meals · 2025-11-19 | Tarpeyo | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-07 | Farxiga | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-11-05 | Jynarque | $25 |
| Fresenius USA Marketing | Meals · 2025-11-05 | Velphoro | $22 |
| Fresenius USA Marketing | Meals · 2025-10-31 | Velphoro | $25 |
| Otsuka America Pharmaceutical | Meals · 2025-10-24 | Jynarque | $25 |
| Novartis Pharmaceuticals | Meals · 2025-10-21 | Fabhalta | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-21 | Farxiga | $23 |
| Fresenius USA Marketing | Meals · 2025-10-20 | Velphoro | $21 |
| Novartis Pharmaceuticals | Meals · 2025-10-10 | Fabhalta | $35 |
| Apellis Pharmaceuticals | Meals · 2025-09-25 | Empaveli | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-20 | Farxiga | $29 |
| Fresenius USA Marketing | Meals · 2025-09-17 | Velphoro | $23 |
| OPKO Pharmaceuticals | Education · 2025-09-16 | Rayaldee | $14 |
| Otsuka America Pharmaceutical | Meals · 2025-09-09 | Jynarque | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-29 | Farxiga | $26 |
| Otsuka America Pharmaceutical | Meals · 2025-08-28 | Jynarque | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-20 | Farxiga | $17 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | Fabhalta | $31 |
| Amgen | Meals · 2025-08-18 | Tavneos | $31 |
| Novartis Pharmaceuticals | Meals · 2025-08-13 | Fabhalta | $33 |
| Fresenius USA Marketing | Meals · 2025-08-12 | Velphoro | $23 |
| Amgen | Meals · 2025-08-08 | Krystexxa | $30 |
| Fresenius USA Marketing | Meals · 2025-07-28 | Velphoro | $25 |
| Aurinia Pharma U.S. | Meals · 2025-07-18 | Lupkynis | $28 |
| Fresenius USA Marketing | Meals · 2025-07-08 | Velphoro | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-03 | Farxiga | $21 |
| Fresenius USA Marketing | Meals · 2025-06-25 | Velphoro | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-14 | Kerendia | $28 |
| Fresenius USA Marketing | Meals · 2025-06-12 | Velphoro | $25 |
| Fresenius USA Marketing | Meals · 2025-05-27 | Velphoro | $22 |
| Fresenius USA Marketing | Meals · 2025-05-20 | Velphoro | $25 |
| Travere Therapeutics | Meals · 2025-05-14 | None | $33 |
| Mallinckrodt Hospital Products | Meals · 2025-05-09 | Acthar | $21 |
| Novartis Pharmaceuticals | Meals · 2025-05-05 | Fabhalta | $22 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | Fabhalta | $17 |
| Fresenius USA Marketing | Meals · 2025-05-01 | Velphoro | $24 |
| Travere Therapeutics | Meals · 2025-04-29 | None | $4 |
| Otsuka America Pharmaceutical | Meals · 2025-04-21 | Jynarque | $1 |
| Otsuka America Pharmaceutical | Meals · 2025-04-21 | Jynarque | $24 |
| Mallinckrodt Hospital Products | Meals · 2025-04-16 | Acthar | $28 |
| Ardelyx | Meals · 2025-04-16 | Ibsrela | $30 |
| Fresenius USA Marketing | Meals · 2025-04-01 | Velphoro | $20 |
| Novartis Pharmaceuticals | Meals · 2025-03-28 | Fabhalta | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-27 | Farxiga | $18 |
| Fresenius USA Marketing | Meals · 2025-03-21 | Velphoro | $7 |
| Fresenius USA Marketing | Meals · 2025-03-21 | Velphoro | $17 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-15 | Kerendia | $35 |
| Vifor Pharma | Meals · 2025-03-14 | Veltassa | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-14 | Farxiga | $23 |
| Mallinckrodt Hospital Products | Meals · 2025-03-12 | Acthar | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-03-12 | Jynarque | $29 |
| OPKO Pharmaceuticals | Education · 2025-03-06 | Rayaldee | $19 |
| Fresenius USA Marketing | Meals · 2025-02-26 | Velphoro | $25 |
| ANI Pharmaceuticals | Meals · 2025-02-21 | Purified Cortrophin Gel | $28 |
| Fresenius USA Marketing | Meals · 2025-02-17 | Velphoro | $24 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Fabhalta | $34 |
| OPKO Pharmaceuticals | Education · 2025-01-31 | Rayaldee | $19 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-25 | Kerendia | $27 |
| Fresenius USA Marketing | Meals · 2025-01-15 | Velphoro | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,284
| Novartis Pharmaceuticals | Fabhalta | $249 | 10 payments
|
| Amgen | Krystexxa | $217 | 8 payments
|
| Fresenius USA Marketing | Velphoro | $162 | 8 payments
|
| Otsuka America Pharmaceutical | Jynarque | $152 | 6 payments
|
| Ardelyx | Ibsrela | $86 | 3 payments
|
| Vifor Pharma | Veltassa | $83 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $64 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $52 | 3 payments
|
| Aurinia Pharma U.S. | Lupkynis | $49 | 2 payments
|
| Novo Nordisk | Ozempic | $35 | 2 payments
|
| Travere Therapeutics | None | $27 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $26 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $26 | 1 payment
|
| Lilly USA | Jardiance | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $19 | 1 payment
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $14 | 1 payment
|
2023: $1,024
| AstraZeneca Pharmaceuticals LP | Farxiga | $262 | 11 payments
|
| Fresenius USA Marketing | Velphoro | $153 | 10 payments
|
| Otsuka America Pharmaceutical | Jynarque | $153 | 7 payments
|
| Calliditas Therapeutics US | Tarpeyo | $77 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $75 | 3 payments
|
| Horizon Therapeutics plc | Krystexxa | $70 | 4 payments
|
| Novartis Pharmaceuticals | None | $64 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $59 | 2 payments
|
| Travere Therapeutics | None | $31 | 2 payments
|
| GlaxoSmithKline | Benlysta | $25 | 1 payment
|
| La Jolla Pharmaceutical | Xerava | $24 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $17 | 1 payment
|
| Novo Nordisk | Ozempic | $13 | 1 payment
|
2022: $519
| Oyster Point Pharma | Tyrvaya | $119 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $100 | 4 payments
|
| Fresenius USA Marketing | Velphoro | $93 | 5 payments
|
| Otsuka America Pharmaceutical | Jynarque | $67 | 3 payments
|
| Exeltis USA | Purified Cortrophin Gel | $61 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $39 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $25 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $15 | 1 payment
|
2021: $80
| Horizon Therapeutics plc | Krystexxa | $34 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $13 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $12 | 1 payment
|
2020: $526
| AstraZeneca Pharmaceuticals LP | Lokelma | $270 | 12 payments
|
| Mallinckrodt Hospital Products | Acthar | $167 | 7 payments
|
| OPKO Pharmaceuticals | Rayaldee | $48 | 3 payments
|
| Amgen | Parsabiv | $21 | 1 payment
|
| Akebia Therapeutics | Auryxia | $20 | 1 payment
|
2019: $101
| Amgen | Parsabiv | $31 | 1 payment
|
| Relypsa | Veltassa | $24 | 1 payment
|
| Mallinckrodt Enterprises | Acthar | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $21 | 1 payment
|
Professional record
- NPI
- 1386807402
- Licence
- CA A106132California A106132: Current · expires 2028-08-31
- Trained
- Stanford University School of Medicine, 2007 · 19 years ago
- Group
- West Coast Kidney
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 13851 E 14th St Ste 206, San Leandro, CA, 94578
- NPI first listed
- 2008-07-09
- NPI last updated
- 2013-12-04
This is when the NPI record was last certified, not a medical board exam.